Roivant Sciences Ltd (ROIV) is an innovative biopharmaceutical company dedicated to revolutionizing the drug development and commercialization landscape through its unique business model and advanced technologies. The company boasts a robust pipeline that targets significant unmet medical needs across neurology, immunology, and rare diseases, positioning itself to efficiently navigate the complexities of drug development while minimizing costs. Led by a seasoned team and supported by strategic partnerships, Roivant aims to deliver both financial growth and enhanced patient outcomes, making it a compelling opportunity for institutional investors.
| Revenue (TTM) | $8.26M |
| Gross Profit (TTM) | $-673.94M |
| EBITDA | $-1.28B |
| Operating Margin | -14675.00% |
| Return on Equity | -7.59% |
| Return on Assets | -14.30% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $6.29 |
| Price-to-Book | 5.58 |
| Price-to-Sales (TTM) | 3161.83 |
| EV/Revenue | 2553.36 |
| EV/EBITDA | 0.74 |
| Quarterly Earnings Growth (YoY) | -96.10% |
| Quarterly Revenue Growth (YoY) | -66.70% |
| Shares Outstanding | $719.27M |
| Float | $563.99M |
| % Insiders | 23.39% |
| % Institutions | 75.90% |
Volatility is currently contracting
Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant's IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis, with ACR20/50/70 rates of 72.7%, 54.5%, and 35.8%, respectively. ROIV's financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to profitability.
Immunovant reports clinically meaningful trial results for its lead drug candidate. That's good news for Roivant Sciences.
Roivant Sciences NASDAQ: ROIV executives used the company's fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary hypertension data for mosliciguat and continued preparation for a potential brepocitinib launch in dermatomyositis.
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.26.
BASEL, Switzerland and LONDON and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provided a business update.
Montes Archimedes Acquisition (ROIV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update at 8:00 a.m.
